Ozempic, Wegovy and the New Generic: What GLP-1s Really Cost in Canada (2026)

Canada quietly became one of the most interesting GLP-1 markets in the world in 2026: the first generic semaglutide arrived, cash prices started falling fast, and yet public coverage for weight loss remains essentially zero. The result is a confusing landscape where one person pays $25 a month through work benefits, another pays $500 out of pocket for the same molecule, and a third discovers the generic at a warehouse pharmacy for under $100. Here is the honest map.

In short

• Generic semaglutide is now approved and selling in Canada, with cash prices at some large pharmacies of roughly $88 to $99 a month, and brand prices responding.
• No provincial drug plan covers Wegovy for weight management. Public coverage of semaglutide remains tied to type 2 diabetes.
• Out-of-pocket brand costs run about $250 to $300 for Ozempic and $400 to $570 for Wegovy.
• Roughly a third of employer benefit plans now include some GLP-1 weight-loss coverage, which is the main route to paying little.
• Generic and brand must meet the same bioequivalence standard, so "is the generic weaker" worries are the usual generic anxieties, not evidence.

What changed in 2026?

Health Canada approved generic semaglutide, and it reached pharmacy shelves at prices far below the brands, which is already dragging the whole market down. Canada is among the first major markets with a generic version of the world's most famous weight-loss molecule, and community discussion moved within weeks from "is it real" to comparing pharmacy prices. Cash prices around $88 to $99 a month have been reported at large chains, as CBC News reported, and some brand pricing has already fallen to meet it. If you were priced out at $400, the calculation has genuinely changed this year.

Does any province cover it for weight loss?

No. As of 2026, every provincial formulary limits public semaglutide coverage to type 2 diabetes, and none covers Wegovy for weight management. If you have type 2 diabetes, Ozempic may be covered subject to your province's criteria. If your indication is obesity without diabetes, the public plans will not pay, whatever your BMI or your doctor's opinion. That is a policy position, not a medical one, and it is why the practical answers all run through private insurance or cash.

What will I actually pay?

Between roughly $88 and $570 a month depending on which product, which pharmacy, and whether any insurance applies. The honest ladder looks like this:

• Employer benefits with GLP-1 coverage: potentially $25 to $100 a month after co-insurance. About a third of employer plans now include some weight-loss GLP-1 coverage, so check your booklet before assuming.
• Generic semaglutide, cash: roughly $88 to $99 a month at the cheapest large pharmacies, higher elsewhere.
• Ozempic, cash: typically $250 to $300 a month.
• Wegovy, cash: typically $400 to $570 a month.
• Telehealth subscriptions: convenient, but compare their all-in monthly cost against a straight pharmacy cash price for the generic; the pharmacy is often now cheaper.

Manufacturer savings cards and programs exist and change frequently, so ask the pharmacy what applies to your product this month.

Is the generic as good as the brand?

It must prove bioequivalence to be approved, so the active molecule and its delivery are held to the same standard; the anxieties around it are the standard generic-switch worries. Within weeks of launch, forums filled with "is the generic less effective" threads. That question has a well-established answer that applies to any approved generic, and we cover it fully in are all generics really the same. The short version: the approval standard is strict, the differences that exist are in fillers and devices, and expectation effects are powerful. If the pen device differs from what you know, ask the pharmacist to walk you through it.

What about compounded semaglutide and microdosing?

The compounded route matters far less in Canada now that a cheap generic exists, and the broader compounding story is tightening anyway. The compounded and microdosing world grew out of shortage and price desperation, and we cover its 2026 state in compounded GLP-1s and microdosing. With generic pricing under $100, the honest Canadian calculus in 2026 mostly favours the regulated product. And for the "natural Ozempic" supplement pitches, our berberine reality check covers why they are not a substitute. Older options like metformin remain part of the diabetes toolkit a doctor may consider. Browse weight loss and diabetes for the medicines in context.

The bottom line

In Canada in 2026, the GLP-1 question has shifted from "can I get it" to "which route is sanest for my wallet." Public plans still say no to weight loss, but generic semaglutide has cut the cash floor to double digits, employer plans increasingly say yes, and brand prices are following the generic down. Check your benefits first, price the generic second, and treat anything more expensive as needing a reason. Coverage rules differ by province, so confirm what applies where you live.

This article is educational and does not replace advice from a doctor or pharmacist who knows your health history.